The determinants of tumour immunogenicity
- 1 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 12 (4), 307-313
- https://doi.org/10.1038/nrc3246
Abstract
Four leading tumour immunologists provide their opinions on the determinants of immunogenicity and how we might therapeutically improve tumour immunogenicity in the future. Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.Keywords
This publication has 70 references indexed in Scilit:
- Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide AptamersMolecular Therapy, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayNature, 2010
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- On the definition of a criterion of immunogenicityProceedings of the National Academy of Sciences, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002